BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20661695)

  • 1. Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease.
    Kurata S; Ishibashi M; Azuma K; Kaida H; Takamori S; Fujimoto K; Kobayashi M; Hirose Y; Aizawa H; Hayabuchi N
    Jpn J Radiol; 2010 Jul; 28(6):446-52. PubMed ID: 20661695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
    Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
    J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
    Mavi A; Basu S; Cermik TF; Urhan M; Bathaii M; Thiruvenkatasamy D; Houseni M; Dadparvar S; Alavi A
    Mol Imaging Biol; 2009; 11(5):369-78. PubMed ID: 19472014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
    Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
    Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of FDG PET-CT in differential diagnosis of pleural pathologies.
    Elboga U; Yılmaz M; Uyar M; Zeki Çelen Y; Bakır K; Dikensoy O
    Rev Esp Med Nucl Imagen Mol; 2012; 31(4):187-91. PubMed ID: 23067687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.
    Bayram M; Dongel I; Akbaş A; Benli I; Akkoyunlu ME; Bakan ND
    Lung; 2014 Feb; 192(1):197-203. PubMed ID: 24170217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.
    Cristaudo A; Foddis R; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Canessa PA; Chella A; Lucchi M; Mussi A; Mutti L
    Int J Biol Markers; 2010; 25(3):164-70. PubMed ID: 20878622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.
    Francis RJ; Segard T; Morandeau L; Lee YC; Millward MJ; Segal A; Nowak AK
    Lung Cancer; 2015 Oct; 90(1):55-60. PubMed ID: 26259878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
    Sharif S; Zahid I; Routledge T; Scarci M
    Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pleural and parenchymal lung diseases from asbestos exposure. CT diagnosis].
    Polverosi R; Vigo M; Citton O
    Radiol Med; 2000 Nov; 100(5):326-31. PubMed ID: 11213409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
    Lim JH; Choi JY; Im Y; Yoo H; Jhun BW; Jeong BH; Park HY; Lee K; Kim H; Kwon OJ; Han J; Ahn MJ; Kim J; Um SW
    PLoS One; 2020; 15(2):e0229299. PubMed ID: 32069313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication.
    Bille A; Chicklore S; Okiror L; Cook GJ; Spicer J; Landau D; Lang-Lazdunski L
    Nucl Med Commun; 2013 Nov; 34(11):1075-83. PubMed ID: 23963351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
    Pinelli V; Roca E; Lucchini S; Laroumagne S; Loundou A; Dutau H; Maldonado F; Astoul P
    Respiration; 2015; 89(6):558-64. PubMed ID: 25966972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
    Wilcox BE; Subramaniam RM; Peller PJ; Aughenbaugh GL; Nichols Iii FC; Aubry MC; Jett JR
    Clin Lung Cancer; 2009 Jul; 10(4):244-8. PubMed ID: 19632941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asbestos related pleuropulmonary lesions and the erythrocyte sedimentation rate.
    Hillerdal G
    Thorax; 1984 Oct; 39(10):752-8. PubMed ID: 6495243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
    Lopci E; Zucali PA; Ceresoli GL; Perrino M; Giordano L; Gianoncelli L; Lorenzi E; Gemelli M; Santoro A; Chiti A
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):667-75. PubMed ID: 25403555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
    Genestreti G; Moretti A; Piciucchi S; Tiseo M; Bersanelli M; Scarlattei M; Scarpi E; Dubini A; Matteucci F; Sanna S
    Technol Cancer Res Treat; 2012 Apr; 11(2):163-7. PubMed ID: 22335410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
    Marin-Oyaga VA; Salavati A; Houshmand S; Pasha AK; Gharavi M; Saboury B; Basu S; Torigian DA; Alavi A
    Hell J Nucl Med; 2015; 18(1):11-8. PubMed ID: 25679073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
    Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
    Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma.
    Subramaniam RM; Wilcox B; Aubry MC; Jett J; Peller PJ
    J Med Imaging Radiat Oncol; 2009 Apr; 53(2):160-9; quiz 170. PubMed ID: 19527361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.